Recombinant Streptokinase Versus Urokinase in Pulmonary Embolism in China (RESUPEC)
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
Recombinant streptokinase (r-SK) is an effective thrombolytic agent developed with gene
engineering. Its characteristics of high output and low production cost make it affordable in
treating acute myocardial infarction (AMI) in developing countries. It is unclear whether
r-SK can be used in patients with pulmonary embolism (PE). The aim of this study was to
investigate the efficacy and safety of 1.5 million IU r-SK by 2 hours infusion and 20,000
IU/kg urokinase (UK) by 2 hours infusion in selected PE patients.
Phase:
Phase 4
Details
Lead Sponsor:
Beijing Chao Yang Hospital
Collaborators:
General Hospital of Shenyang Military Region Guangdong Institute of Respiratory Disease Ningxia Medical University Qingdao University Shenzhen People's Hospital The First Affiliated Hospital of Shanxi Medical University Tianjin Medical University General Hospital